The Food and Drug Administration has approved Pluvicto for men whose metastatic prostate cancer still responds to hormone therapy, a change that Novartis says nearly doubles the number of patients eligible for the treatment. The decision, announced July 31, allows the radioligand therapy to be used in combination with an androgen receptor pathway inhibitor much earlier in the disease than before.
For patients, the practical question that follows is not whether the drug works. It is whether they can get to a place that is legally permitted to give it.
